Spero Health Roanoke

Spero Health Roanoke is a SAMHSA-registered addiction-treatment facility in Lexington, KY. The facility's programming is outpatient (Outpatient, MAT), not residential. This page frames the questions that matter most when evaluating a specific program — the ones that separate useful candidates from marginal ones.

Care levels at Spero Health Roanoke

Spero Health Roanoke is an outpatient-focused program (Outpatient, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. ASAM Criteria 4e is the benchmark framework for matching patients to appropriate intensity. Most major payer medical-necessity documents reference it. An outside ASAM-aligned assessment, prior to admission, is the protection against misplacement.

Insurance and payment

Spero Health Roanoke accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. The facility also accepts TRICARE or military benefits. Before admission, request a written Verification of Benefits from the facility's utilization-review team. Verbal VOB is where most post-admission cost-sharing disputes originate. Written documentation settles them.

Specialty programming

The facility's documented specialty programming includes: Adult women, Pregnant/postpartum women, Adult men. Specialty designations benefit from specific follow-up: programming hours per week, credentialed staff profile, integrated assessment protocols. Dual-diagnosis as a marketing category differs from operational specialty infrastructure.

Before you call

The operational due diligence on Spero Health Roanoke comes down to three documents: ASAM-aligned level-of-care documentation matching independent clinical assessment, written Verification of Benefits for your specific plan product, written MAT policy. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.